Merck drug no “significant efficacy” against moderate COVID: India regulatory source

NEW DELHI, Oct 8 (Reuters) – Merck & Co’s (MRK.N) experimental antiviral drug molnupiravir has not shown “significant efficacy” against moderate COVID-19, a source with the Drug Controller General of India said.

Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate COVID-19 patients, the regulator’s expert committee said on Friday.

link

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s